SCHEMBL7718876

SCHEMBL7718876

CCOC(=O)C(CC)C(C)C(C)CP(=O)(O)O

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 2/20 0.33
LAP3 P28838 1/20 0.31
ALDH1A1 P00352 3/20 0.31
CYP3A4 P08684 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
METAP1 P53582 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7716778 0.89 CYP2D6 (0.39) CYP2D6CYP2C9CYP2C19HSD17B10LAP3
SCHEMBL6132143 0.78 CYP2D6 (0.41) CYP2D6CYP2C9CYP2C19HSD17B10LAP3
SCHEMBL7715964 0.78 CYP2D6 (0.41) CYP2D6CYP2C9CYP2C19HSD17B10LAP3
SCHEMBL11318860 0.75 MEN1 (0.34) CYP2D6HSD17B10ALDH1A1ALOX15TDP1
SCHEMBL7714685 0.75 METAP1 (0.42) CYP2D6CYP2C9CYP2C19LAP3ALDH1A1
SCHEMBL17617126 0.73 ALDH1A1 (0.42) CYP2C19HSD17B10ALDH1A1CYP3A4ALOX15
SCHEMBL17617134 0.73 ALDH1A1 (0.42) CYP2C19HSD17B10ALDH1A1CYP3A4ALOX15
SCHEMBL17617122 0.73 ALDH1A1 (0.42) CYP2C19HSD17B10ALDH1A1CYP3A4ALOX15
SCHEMBL235849 0.72 ALDH1A1 (0.50) HSD17B10ALDH1A1ALOX15TSHRLMNA
SCHEMBL19557119 0.72 ALDH1A1 (0.37) CYP2C19HSD17B10ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed